Alpha Clinics: Making the Future a Reality for Stem Cell-Based Therapies
This symposium, held at City of Hope on March 23, 2017, highlighted the goals of the CIRM ASCC Network, focusing on what has been achieved to date and discussing the pathways towards commercialization and reimbursement of newly developed therapies. TED-style talks and round table discussions brought together a broad array of stakeholders, including investigators, patient advocates, regulators, payors, and government representatives for brainstorming and insights.
The CIRM Alpha Stem Cell Clinics (ASCC) Network consists of three clinical centers of excellence committed to accelerating the delivery of stem cell therapies. Alpha Clinics are located at City of Hope, UC San Diego, and UCLA in collaboration with UC Irvine.
- Geoff Lomax, Dr. PH, CIRM Senior Officer, will speak about “The mission and distinguishing features of the CIRM Alpha Stem Cell Clinics Network.”
- Pat Furlong, Founding President and CEO of Parent Project Muscular Dystrophy, will deliver a Keynote Address on “Removing stakeholder barriers to stem cell therapy”
- Dr. Rachel Salzman of The Stop ALD Foundation will speak about treatment development utilizing modern technologies such as gene and stem cell therapies
- In a series of TED-like talks, each Alpha Clinic will highlight specific stem cell-based therapies in terms of current activities and pathways to success.
- A Model Roundtable/Panel Discussion will address the symposium goal from the perspectives of clinicians, patient advocates, payors, government regulators, and CIRM.
- Representatives from Adicet Bio, jCyte, Calimmune and Oncternal Therapeutics will highlight pharma/biotech paths to successful stem cell-based therapies
- Welcome Address
- Introduction of Morning Sessions
- Keynote Address I: CIRM's Role in Advancing Stem Cell-Based Therapies
- Stem Cell Therapy: Value and Reimbursement Considerations
- All in: Turning the Alpha Clinic Vision into a Reality for Patients
- Retinal Progenitor Cells for Treatment of Retinitis Pegmentosa
- Second Vision: A Light at the End of the Tunnel
- Corneal Regeneration: Now and Beyond
- Keynote Address II: Removing Stakeholder Barriers to Stem Cell Therapy
- Cancer Stem Cell Targeting with Cirmtuzumab
- Oncternal Therapeutics and the Promise of Cancer Stem Cell Therapy
- Clinical Observations from the Phase 1 Trial of Cirmtuzumab
- Novel Education: We Give Patients What They Want in Trials - iPad
- Bringing Patients, Industry, Principal Investigators and Regulators Together
- CAR T Cell Therapy: Challenges and Lessons Learned
- Clinical Trial of IL13r-CAR T Cells for Glioblastoma
- Considerations and Strategies for Bringing T Cell Products to the Market
- The Center for Biomedicine and Genetics: A Biological Forge
- Keynote Address III: The Public's Role in Advancing Stem Cell-based Therapies
- Negotiating Global Regulatory Pathways for Cell Based Therapies
- What it Will Take to Bring Stem Cell Gene Therapy to All Who Can Benefit From It
- Model Roundtable: The Alpha Clinics and the Future
- The Shape of Things to Come-Stem Cells and the Lives of Real People